Telix and Regeneron Announce Strategic Radiopharma Collaboration

Telix and Regeneron Announce Strategic Radiopharma Collaboration

Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model.Collaboration combines Telix's...

Regeneron wades into radiopharma through $40M upfront deal with Telix

Regeneron is set to work on radiopharmaceuticals for the first time in a new partnership to develop solid tumor therapies as well as diagnostic agents with Telix Pharmaceuticals. Under the 50/50 ...

Telix and Regeneron to co-develop radiopharmaceutical therapies

Telix and Regeneron have entered a partnership for the development and commercialisation of new radiopharmaceutical therapies.

Telix Pharmaceuticals (ASX:TLX) Is Up 13.1% After Regeneron Tie-Up And FDA NDA Acceptance For TLX101-Px

In early April 2026, Telix Pharmaceuticals and Regeneron Pharmaceuticals announced a global 50/50 cost- and profit-sharing collaboration to co-develop next-generation radiopharmaceutical cancer therapies, alongside US$40 million upfront and the potential for up to US$2.10 billion in milestones and royalties to Telix. Within days, the U.S. FDA accepted Telix’s resubmitted New Drug Application for its brain cancer imaging agent TLX101-Px (Pixclara…

Health Check: Telix strikes surprise $3 billion-plus headline deal to develop next-gen therapies

Telix shares surge up to 9% after this morning’s surprise deal with Regeneron Relating to therapies not yet being developed by Telix, the compact includes a US$40 million upfront payment Oh baby! Genesis returns with improved Monash IVF offer   Telix Pharmaceuticals (ASX:TLX) has blindsided short sellers with a left-field big pharma deal to develop nuclear medicine cancer therapies for “multiple solid tumour targets” in the biologics sector. The…

Telix Pharmaceuticals (ASX:TLX) Regeneron $14b revenue partner, 49m shorts face pressure

$40m Regeneron cheque validates RLS as 49m shorts watch Telix Pharmaceuticals (ASX:TLX) is building momentum after the positive NDA update for Pixclara, its PET imaging agent for glioma, a form of brain cancer. Today, the company added to that momentum by announcing a 50/50 partnership with Regeneron to develop and commercialise a new generation of…